Results of literature searcha
| Study | No.b | FU Time (mo) | % Inactive Patients (Placebo) | Efficacy Measure | |||
|---|---|---|---|---|---|---|---|
| Absolute % Increase in Inactive Patients | Lesion No. (All Patients) | Lesion Volume (All Patients) | Lesion Volume (Active Patients) | ||||
| Oral temsirolimus | 120 | 9 | 25% | +2% | −26% | −29% | −26% |
| Glatiramer acetate | 239 | 9 | 5% | −2% | −33%c | −42% | −43% |
| Natalizumab | |||||||
| 3 mg | 139 | 6 | 32% | +43% | −88% | −87% | −64% |
| 6 mg | 145 | 6 | 32% | +33% | −82% | −76% | −54% |
| Oral fingolimod | |||||||
| 1.25 mg | 164 | 6 | 47% | +30% | −43% | −50% | +16% |
| 5 mg | 158 | 6 | 47% | +35% | −61% | −63% | +10% |
| Overall mean effect | 13% | 56% | 58% | 27% | |||
Note:—FU indicates follow-up.
↵a Effects shown are the percentage increase in active patients, the percentage change in mean or median number of lesions, the percentage change in mean lesion volume in the complete cohort, and the percentage change in mean lesion volume in active patients.
↵b Total number of participating patients in trial.
↵c Median lesion number.